



7 April 2020

Sydney, Australia

Noxopharm trial data to be presented at ASCO 2020

Sydney, 7 April 2020: Noxopharm (ASX:NOX) is pleased to announce that two poster presentations and one abstract online publication relating to the Company's lead product candidate, NOX66, have been accepted for the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May to 2 June 2020. ASCO is a globally leading scientific meeting for oncology professionals attracting 42,500 attendees last year.

Due to the impact of COVID-19, ASCO this year is being held in a virtual format with posters and abstracts being published online.

Dr Gisela Mautner, Chief Medical Officer, said, "The ASCO Annual Scientific Meeting is one of the most prestigious and biggest oncology conferences in the world. It received a record number of submissions this year for presentation, so given the competition, we are delighted to have had all 3 submissions accepted.

The DARRT presentation will detail the final results of the study and the LuPIN poster will provide updated data of the ongoing trial."

Noxopharm will provide details about the two posters via the ASX platform following their release during the conference.

DARRT-1 Poster Presentation

Poster Title: Phase 1 study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer.

Presenter: Professor Paul de Souza

LuPIN Poster Presentation

Poster Title: Updated results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men



with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).

Presenter: Associate Professor Louise Emmett

Dr Olivier Laczka, Director of Drug Discovery and Research, said, "The abstract online publication refers to a pre-clinical collaboration with The University of Hong Kong and is the subject of a Bridging Grant from the Australian Academy of Technology & Engineering awarded to Noxopharm and The University of Hong Kong. This grant is directed specifically towards gaining a deeper understanding of the mechanisms behind NOX66's immuno-oncology properties and developing a treatment for nasopharyngeal carcinoma, a common cancer endemic to Southern China and with generally poor treatment outcomes. This work is intended to provide a platform for taking Veyonda® into a clinical trial in China."

Nasopharyngeal Carcinoma Preclinical Study Abstract

Online abstract title: Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma.

Publication date: 14 May 2020, AEST

Authors: N-W Kam, V H-F Lee et al.

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR).
www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.



Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.